Abstract
No public abstract is available from the verified source records.
Anne R. Bass
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
10.1136/jitc-2021-002896 · 2021
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · 2018
A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
10.1002/ijc.32132 · 2019
Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis
10.1001/jamaoncol.2018.3923 · 2018
Spectrum and impact of checkpoint inhibitor-induced irAEs
10.1038/s41584-020-00546-2 · 2021
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study
10.1136/annrheumdis-2017-212257 · 2018
Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series
10.1097/rhu.0000000000001370 · 2021
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study
10.1136/jitc-2025-014641 · 2026
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
10.1136/jitc-2021-003260 · 2021
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
10.1136/annrheumdis-2019-216109 · 2020
Higher checkpoint inhibitor arthritis disease activity may be associated with cancer progression: results from an observational registry
10.1002/acr2.11181 · 2020
Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy
10.1136/jitc-2019-000281 · 2020
Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis
10.1126/sciimmunol.add1591 · 2023
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
10.1038/s41467-022-29539-3 · 2022
Single-cell profiling identifies IL1Bhi macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis
10.1038/s41467-024-46195-x · 2024
Tumor microenvironment as a therapeutic target in melanoma treatment
10.3390/cancers15123147 · 2023
Defining T cell states associated with response to checkpoint immunotherapy in melanoma
10.1016/j.cell.2018.12.034 · 2019
CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers
10.1126/science.ade2292 · 2023
IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer
10.1038/s41586-023-06685-2 · 2023
The fibroinflammatory response in cancer
10.1038/s41568-025-00798-8 · 2025
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression
10.1016/j.celrep.2017.04.031 · 2017
Mutations Associated with Acquired Resistance to PD-1 blockade in melanoma
10.1056/nejmoa1604958 · 2016
Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis
10.1158/2159-8290.cd-22-1180 · 2023
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
10.1136/ard-2023-223885 · 2023
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
10.1016/j.annonc.2024.08.2340 · 2025
Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials
10.1200/jco.24.00191 · 2024
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS registry study
2026
Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials
10.1200/jco.24.00191 · doi-reference
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
10.1016/j.annonc.2024.08.2340 · doi-reference
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
10.1136/ard-2023-223885 · doi-reference
Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis
10.1158/2159-8290.cd-22-1180 · doi-reference
Mutations Associated with Acquired Resistance to PD-1 blockade in melanoma
10.1056/nejmoa1604958 · doi-reference
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression
10.1016/j.celrep.2017.04.031 · doi-reference
The fibroinflammatory response in cancer
10.1038/s41568-025-00798-8 · doi-reference
IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer
10.1038/s41586-023-06685-2 · doi-reference
CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers
10.1126/science.ade2292 · doi-reference
Defining T cell states associated with response to checkpoint immunotherapy in melanoma
10.1016/j.cell.2018.12.034 · doi-reference
Tumor microenvironment as a therapeutic target in melanoma treatment
10.3390/cancers15123147 · doi-reference
Single-cell profiling identifies IL1Bhi macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis
10.1038/s41467-024-46195-x · doi-reference
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
10.1038/s41467-022-29539-3 · doi-reference
Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis
10.1126/sciimmunol.add1591 · doi-reference
Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy
10.1136/jitc-2019-000281 · doi-reference
Higher checkpoint inhibitor arthritis disease activity may be associated with cancer progression: results from an observational registry
10.1002/acr2.11181 · doi-reference
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
10.1136/annrheumdis-2019-216109 · doi-reference
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
10.1136/jitc-2021-003260 · doi-reference
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study
10.1136/jitc-2025-014641 · doi-reference
Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series
10.1097/rhu.0000000000001370 · doi-reference
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study
10.1136/annrheumdis-2017-212257 · doi-reference
Spectrum and impact of checkpoint inhibitor-induced irAEs
10.1038/s41584-020-00546-2 · doi-reference
Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis
10.1001/jamaoncol.2018.3923 · doi-reference
A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
10.1002/ijc.32132 · doi-reference
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · doi-reference
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
10.1136/jitc-2021-002896 · doi-reference